Corvus Pharmaceuticals leaps after launching phase one trial for Covid-19 treatment
Corvus Pharmaceuticals, Inc. Common Stock
$1.51
11:05 24/04/24
-1.31%
-$0.02
Stock in US-based Corvus Pharmaceuticals nearly doubled on Tuesday after announcing its plans to launch an early state clinical trial for an experimental monoclonal antibody to treat Covid-19.
The biotechnology outfit said that it would recruit as many 30 volunteers with mild-to-moderate symptoms from the novel coronavirus.
"Our B cell activating monoclonal antibody may be a potential immunotherapy for COVID-19 based on its ability to stimulate the production of anti-SARS-CoV-2 antibodies," the firm said in a statement.
Data from the study were expected later in 2020.
As of 1439 BST, shares of Corvus Pharmaceuticals were rocketing 84.85% to $5.10.